Cangrelor: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{SI}} {{CMG}} ==Overview== '''Cangrelor''' is a P2Y<sub>12</sub> inhibitor under investigation as an antiplatelet drug<ref name="cat.sagepub.com">[h...") |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Cangrelor''' is a [[P2Y12|P2Y<sub>12</sub>]] inhibitor under investigation as an [[antiplatelet drug]]<ref name="cat.sagepub.com">[http://cat.sagepub.com/cgi/content/abstract/15/2/177 Cangrelor Attenuates Coated-Platelet Formation]</ref> for [[intravenous]] application. Some P2Y<sub>12</sub> inhibitors are used clinically as effective inhibitors of [[adenosine diphosphate]]-mediated platelet activation and aggregation.<ref name="cat.sagepub.com"/> Unlike [[clopidogrel]] (Plavix), which is a [[prodrug]], cangrelor is an active drug not requiring [[metabolism|metabolic]] conversion. | '''Cangrelor''' is a [[P2Y12|P2Y<sub>12</sub>]] inhibitor under investigation as an [[antiplatelet drug]]<ref name="cat.sagepub.com">[http://cat.sagepub.com/cgi/content/abstract/15/2/177 Cangrelor Attenuates Coated-Platelet Formation]</ref> for [[intravenous]] application. Some P2Y<sub>12</sub> inhibitors are used clinically as effective inhibitors of [[adenosine diphosphate]]-mediated [[platelet activation]] and aggregation.<ref name="cat.sagepub.com"/> Unlike [[clopidogrel]] (Plavix), which is a [[prodrug]], cangrelor is an active drug not requiring [[metabolism|metabolic]] conversion. | ||
Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.<ref>[http://www.medscape.com/viewarticle/702828 CHAMPION Trials With Cangrelor Stopped for Lack of Efficacy]</ref> The BRIDGE study, for short term use prior to surgery, continues.<ref>[http://seekingalpha.com/article/137521-what-cangrelor-failure-means-to-medicines What Cangrelor Failure Means to Medicines]</ref> The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac | Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.<ref>[http://www.medscape.com/viewarticle/702828 CHAMPION Trials With Cangrelor Stopped for Lack of Efficacy]</ref> The BRIDGE study, for short term use prior to surgery, continues.<ref>[http://seekingalpha.com/article/137521-what-cangrelor-failure-means-to-medicines What Cangrelor Failure Means to Medicines]</ref> The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac [[stent]]s. Compared with [[clopidogrel]] given around the time of stenting, intravenous [[ADP]]-receptor blockade with cangrelor significantly reduced the rate of [[stent thrombosis]] and [[myocardial infarction]].<ref>Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events (2013) Bhatt, DL etal. New England Journal of Medicine March 10, 2013 {{doi|10.1056/NEJMoa1300815}} (published initially online).</ref> Reviewers have questioned the methodology of the trial.<ref>The Duel between Dual Antiplatelet Therapies (2013) Lange, RA and Hillis, LD. New England Journal of Medicine March 10, 2013 {{doi|10.1056/NEJMe1302504}}</ref> | ||
==References== | ==References== | ||
Revision as of 22:34, 10 March 2014
|
WikiDoc Resources for Cangrelor |
|
Articles |
|---|
|
Most recent articles on Cangrelor |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cangrelor at Clinical Trials.gov Clinical Trials on Cangrelor at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cangrelor
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cangrelor Discussion groups on Cangrelor Directions to Hospitals Treating Cangrelor Risk calculators and risk factors for Cangrelor
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cangrelor |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cangrelor is a P2Y12 inhibitor under investigation as an antiplatelet drug[1] for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.[1] Unlike clopidogrel (Plavix), which is a prodrug, cangrelor is an active drug not requiring metabolic conversion.
Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009.[2] The BRIDGE study, for short term use prior to surgery, continues.[3] The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction.[4] Reviewers have questioned the methodology of the trial.[5]
References
- ↑ 1.0 1.1 Cangrelor Attenuates Coated-Platelet Formation
- ↑ CHAMPION Trials With Cangrelor Stopped for Lack of Efficacy
- ↑ What Cangrelor Failure Means to Medicines
- ↑ Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events (2013) Bhatt, DL etal. New England Journal of Medicine March 10, 2013 doi:10.1056/NEJMoa1300815 (published initially online).
- ↑ The Duel between Dual Antiplatelet Therapies (2013) Lange, RA and Hillis, LD. New England Journal of Medicine March 10, 2013 doi:10.1056/NEJMe1302504